A CAPTCHA is basically a test to prove you're human, and that's what im here to do with my music.
Employees: 1-10
Founded date: 2010
Investors 1
| Date | Name | Website |
| - | Sarsia | sarsia.com |
Mentions in press and media 8
| Date | Title | Description |
| 09.11.2022 | Nordic Nanovector and APIM Therapeutics Announce Merger Agreement | Nordic Nanovector and APIM Therapeutics Announce Merger Agreement Wed, Nov 09, 2022 21:37 CET Report this content NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN... |
| 13.01.2022 | APIM THERAPEUTICS ANNOUNCEs PUBLICATION OF PRECLINICAL RESEARCH OF ATX-101 IN GLIOBLASTOMA | APIM THERAPEUTICS ANNOUNCEs PUBLICATION OF PRECLINICAL RESEARCH OF ATX-101 IN GLIOBLASTOMA Thu, Jan 13, 2022 12:00 CET APIM Therapeutics (APIM), a clinical stage biotech company, focusing on the development of novel peptide therapeutics tar... |
| 10.12.2021 | APIM THERAPEUTICS ANNOUNCES INITIATION OF PATIENT RECRUITMENT IN A SARCOMA PHASE II STUDY | APIM THERAPEUTICS ANNOUNCES INITIATION OF PATIENT RECRUITMENT IN A SARCOMA PHASE II STUDY Fri, Dec 10, 2021 12:00 CET Trondheim/New York, December 10, 2021 APIM Therapeutics (APIM), a clinical stage biotech company focusing on the developme... |
| 25.11.2021 | APIM THERAPEUTICS ANNOUNCES THAT THE FIRST PATIENT HAS BEEN TREATED WITH ATX-101 IN A PHASE I/II OVARIAN CANCER STUDY | APIM THERAPEUTICS ANNOUNCES THAT THE FIRST PATIENT HAS BEEN TREATED WITH ATX-101 IN A PHASE I/II OVARIAN CANCER STUDY Thu, Nov 25, 2021 12:00 CET Trondheim, 25 November 2021 APIM Therapeutics (APIM), a clinical stage biotech company, focusi... |
| 17.10.2012 | APIM Therapeutics Closes Financing | APIM Therapeutics, a Trondheim, Norway-based preclinical biotech company focusing on the development of novel peptide therapeutics targeting PCNA (Proliferating Cell Nuclear Antigen), has closed a financing round of undisclosed amount. The ... |
| 10.11.2011 | APIM Therapeutics Raises Additional Funding | Trondheim Norway-based early-stage therapeutic company APIM Therapeutics has raised additional funding. The investment is provided by Birk Venture, Ro Invest and Sarsia Seed. Led by CEO Konstantinos Alevizopoulos and based on research by Pr... |
| 21.03.2011 | APIM Therapeutics Closes Additional Seed Funding Round | APIM Therapeutics AS, a Trondheim Norway-based early-stage therapeutic company, has closed an additional seed funding round. The investment is provided by existing backer Sarsia Seed AS. Based on an original discovery by Prof. Marit Otterle... |
| 27.05.2010 | APIM Therapeutics AS Raises €440,000 | APIM Therapeutics AS, a spin-out from The Norwegian University of Science and Technology (NTNU), has raised NOK3.5m (approximately €440.000) from Sarsia Seed AS. The company has developed novel peptide drugs, which have the potential to imp... |